Eli Lilly agreed to acquire Bothell, Wash.-based Curevo Vaccine for up to $1.5 billion in cash. The deal centers on a next-generation shingles vaccine that reduced side effects by more than half in a Phase 2 study. Read More
Intelligence View
⚡ tsecurity.de Intelligence
Eli Lilly to acquire Seattle-area biotech in $1.5 billion bet on next-generation shingles vaccine
Eli Lilly agreed to acquire Bothell, Wash.-based Curevo Vaccine for up to $1.5 billion in cash. The deal centers on a next-generation shingles vaccine that reduced side effects by more than half in a Phase 2 study. Read More
Reagiere als Erste:r — dein Feedback zählt!
Eli Lilly agreed to acquire Bothell, Wash.-based Curevo Vaccine for up to $1.5 billion in cash. The deal centers on a next-generation shingles vaccine that reduced side effects by more than half in a Phase 2 study. Read More